Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

• Status: Terminated
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including high blood pressure and chest pain. People with diabetes who receive beta-blockers may experience adverse health effects, but the exact cause of why this happens remains unknown. This study will examine the genetic factors that may influence how atenolol, a beta-blocker medication, affects fat breakdown, blood sugar levels, and heart function in people with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI); University of Maryland, Baltimore
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); University of Maryland
• Treatments: Adrenergic beta-Antagonists; Atenolol

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Pre-Diabetes

Exclusion Criteria:

• Insulin therapy

• Treatment with any beta-blocker in the 30 days before study entry

• Asthma

• Chronic obstructive pulmonary disease (COPD)

• Greater than first degree heart block

• Heart rate less than 60 bpm

• Systolic blood pressure less than 90 mm Hg

• Raynaud's phenomenon

• Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators

• Pregnant

• Creatinine clearance less than 35 ml/min

• Hematologic dysfunction (white blood cell [WBC] count less than 3000 or hematocrit less than 28%)

• Allergy to amide anesthetics